Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 1, 1998, Pages 19-28

  Ruiz, Lidia ^a   Nijhuis, Monique ^b   Boucher, Charles ^b   Puig, Teresa ^a   Bonjoch, Anna ^a   Martínez Picado, Javier ^a   Marfil, Silvia ^a   De Jong, Dorien ^b   Burger, David ^c   Arnó, Albert ^a   Balagué, Montserrat ^d   Clotet, Bonaventura ^a,d  

^a IrsiCaixa Foundation   (Spain)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Advanced HIV 1 patients; Combination therapy; Genotypic resistance; HIV 1; Indinavir; Phenotypic resistance; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS RECOMBINANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 13144267696     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199809010-00003     Document Type: Article

References (21)

1. Markowitz M, Saag M, Powderly W, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
2. Vella S, Lazzarin A, Carosi G, et al. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Ther 1996;1:129-40.
3. Collier A, Coombs R, Schoenfeld D, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011-17.
4. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir [abstract Mo.B.411]. Presented at the XI International Conference on AIDS, Vancouver, July 1996.
5. 3 [abstract M. LB7]. Presented at the IV Conference on Retroviruses and Opportunistic Infections, Washington DC, January 1997.
6. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-601.
7. Schmit J-C, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995-9.
8. Partick AK, Rose R, Greytok J, et al. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 1995;69:2148-52.
9. Condra JH, Schleif O, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
10. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;12:8270-6.
11. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;7:760-6.
12. Jacobsen H, Hänggi M, Ott M et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996;173:1379-87.
13. Schockmel GA, Sabine Y, Perrin L. Detection of low RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:179-83.
14. Burger DM, Graaff M, Koopmans PP, Hekster YA. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reverse-phase high performance liquid chromatography. J Chronuaogr 1997;703:235-41.
15. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillem PME, Van der Nooda J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
16. Maschera B, Furfine E, Blair DE. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995;69:5431-6.
17. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hygiene 1983:493-7.
18. Pauwels R, Balzarini JM, Baba R, et al. Rapid and automated tetrazolium based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.
19. Boucher CAB, Keulen W, Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996;10:2404-9.
20. Lech WJ, Wang G, Yang YL, et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-43.
21. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996;7:753-9.